Cellectar Biosciences enrolled its first patient in its Phase 1b clinical trial evaluating iopofosine I 131 in pediatric patients with relapsed or refractory malignant high-grade gliomas (pHGG), the company announced today.
According to a release, the open-label study will assess two dosing regimens to identify the optimal iopofosine I 131 Phase 2 recommended dose and schedule in pHGGG patients and evaluate safety and tolerability.
.@madisoncollege, @MATCMilwaukee, @UniversitiesWI bolster accessibility of #biohealth #career pathways. via @ibmadison
Madison College, MATC, UW bolster accessibility of biohealth career pathways
The ABC Pathways project aims to train and place 2,000 workers in biohealth jobs within five years, with a 30% employee diversity goal.
loom.ly
The state of early stage investing in #Wisconsin: How did 2023 fare?
Learn more at our #Innovation Network luncheon 7/23 in #Madison. https://loom.ly/q2Q6Gk0 #startup
.@uwmadison scientists are testing a new soil nutrient sensor this summer. https://loom.ly/BKfOn_o via @wisbusiness #Wisconsin #agriculture
Event (8/7): '@captimes Power Hour' with @milwaukeetool's Scott Griswold. Learn more: #Wisconsin #business #leadership
The Cap Times Power Hour featuring Scott Griswold of Milwaukee Tool
The Cap Times has established itself as a leader in presenting high-powered events that educate and entertain in t...
loom.ly
A reminder to join us for our annual #golf outing, reception on 7/31!
Learn more: via @ibmadison
Tech Council hosting annual Golf Outing, reception at July’s end
Purchase of an individual or foursome includes golf warm up, lunch, carts, and the end of day reception.
loom.ly
.@michaelbestlaw and Los Angeles-based venture #law firm O&A P.C. complete their combination. #Wisconsin #venturecapital
Michael Best, Los Angeles-Based Venture Law Firm O&A, P.C. Complete Combination
Michael Best and venture law firm O&A, P.C. have formally combined effective July 1, 2024. Through the combination, ...
loom.ly
;
